Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin ...

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...

Meet the Novartis Board of Directors, responsible for the direction, strategy, and administration of this global pharmaceutical and biotech company.

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations.

Improving our environmental footprint contributes to mitigating the impacts of climate change on the planet and on human health. It also allows us to increase the efficiency of our operations. As such ...

Learn what cell and gene therapy is, how it differs from conventional medicine, and why it's creating a new turning point in how we treat disease.

The Novartis Singapore site is their first biologics production facility in Asia and one of the largest biologics manufacturing investments in Singapore. It is aimed to launch and produce innovative ...

Novartis je največji ponudnik inovativnih zdravil v Sloveniji in ključen partner slovenskega zdravstva.

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma ...

Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9 million ...

Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by ...